CO5590960A2 - DERIVATIVES OF AZAINDOLILALQUILAMINA AS LIGANDOS OF 5- HYDROXITRIPTAMINE-6 - Google Patents
DERIVATIVES OF AZAINDOLILALQUILAMINA AS LIGANDOS OF 5- HYDROXITRIPTAMINE-6Info
- Publication number
- CO5590960A2 CO5590960A2 CO04055770A CO04055770A CO5590960A2 CO 5590960 A2 CO5590960 A2 CO 5590960A2 CO 04055770 A CO04055770 A CO 04055770A CO 04055770 A CO04055770 A CO 04055770A CO 5590960 A2 CO5590960 A2 CO 5590960A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- independently
- optionally substituted
- heteroaryl
- optionally
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
1.- Un compuesto de formula I en dondeW es SO2, CO, CONR11 o CSNR12;X es N o CR1;Y es N o CR2; Z es N o CR3;Q es N o CR4 con la condición que no más de dos entre X, Y, Z, y Q puedan ser N;n es un entero 2 o 3;R1, R2, R3 y R4 son cada uno independientemente H, halógeno, CN, OCO2R13, CO2R14, CONR15R16, CNR17NR18R19, SOmR20, NR21R22, OR23, COR24, o un grupo alquiloC1-C6, alqueniloC2-C6, alquiniloC2-C6, cicloalquiloC3-C6, cicloheteroalquilo, arilo o heteroarilo cada uno opcionalmente sustituido;R5 y R6 son cada uno independientemente H o un grupo alquiloC1-C6, alqueniloC2-C6, alquiniloC2-C6, cicloalquiloC3-C6, cicloheteroalquilo, arilo o heteroarilo cada uno opcionalmente sustituido, o R5 y R6 pueden ser tomados juntos con el átomo al cual están unidos para formar un anillo de 5- a 7- miembros opcionalmente sustituido, que contiene opcionalmente un heteroátomo adicional seleccionado de O, N o S;R7 y R8 son cada uno independientemente H o un grupo alquiloC1-C6 opcionalmente sustituido;R9 es H, halógeno o un grupo alquiloC1-C6, alcoxiC1-C6, arilo o heteroarilo cada uno opcionalmente sustituido;R10 es un grupo alquiloC1-C6, arilo o heteroarilo opcionalmente sustituido, o un sistema de anillo bicíclico o tricíclico de 8- a 13- miembros opcionalmente sustituido, que tiene un átomo de N en el puente de la molécula, y opcionalmente contiene 1, 2 o 3 heteroátomos adicionales seleccionados de N, O o S con la condición que cuando Q es N y X, Y y Z son CH, luego R10 debe ser diferente de fenilo.m es 0 o un entero 1 o 2;R11 y R12 son cada uno independientemente H o un grupo alquiloC1-C6, arilo o heteroarilo cada uno opcionalmente sustituido;R13, R14, R20 y R24 son cada uno independientemente H o un grupo alquiloC1-C6, alqueniloC2-C6, alquiniloC2-C6, cicloalquiloC3-C6, cicloheteroalquilo, arilo o heteroarilo cada uno opcionalmente sustituido;R15, R16 y R23 son cada uno independientemente H o un grupo alquiloC1-C6 opcionalmente sustituido; y ...1.- A compound of formula I wherein W is SO2, CO, CONR11 or CSNR12; X is N or CR1; Y is N or CR2; Z is N or CR3; Q is N or CR4 with the condition that no more than two between X, Y, Z, and Q can be N; n is an integer 2 or 3; R1, R2, R3 and R4 are each independently H, halogen, CN, OCO2R13, CO2R14, CONR15R16, CNR17NR18R19, SOmR20, NR21R22, OR23, COR24, or a C1-C6 alkyl group, C2-C6 alkynyl, C2-C6 alkynyl, C3-C6 cycloheteroalkyl each optionally heteroaryl, each heteroaryl alkyl substituted; R5 and R6 are each independently H or a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, cycloheteroalkyl, aryl or heteroaryl optionally each substituted, or R5 and R6 can be taken together with the atom to which they are attached to form an optionally substituted 5- to 7- member ring, optionally containing an additional heteroatom selected from O, N or S; R7 and R8 are each independently H or an optionally substituted C1-C6 alkyl group; R9 is H, halogen or a C1-C6 alkyl, C1-C6 alkoxy, aryl or heteroaryl group each optional Substituted mind; R10 is an optionally substituted C1-C6 alkyl, aryl or heteroaryl group, or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system, having an N atom on the bridge of the molecule, and optionally it contains 1, 2 or 3 additional heteroatoms selected from N, O or S with the proviso that when Q is N and X, Y and Z are CH, then R10 must be different from phenyl.m is 0 or an integer 1 or 2; R11 and R12 are each independently H or an optionally substituted C1-C6 alkyl, aryl or heteroaryl group; R13, R14, R20 and R24 are each independently H or a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl group, C3-C6 cycloalkyl, cycloheteroalkyl, aryl or heteroaryl each optionally substituted: R15, R16 and R23 are each independently H or an optionally substituted C1-C6 alkyl group; Y ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34283801P | 2001-12-20 | 2001-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5590960A2 true CO5590960A2 (en) | 2005-12-30 |
Family
ID=23343489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04055770A CO5590960A2 (en) | 2001-12-20 | 2004-06-15 | DERIVATIVES OF AZAINDOLILALQUILAMINA AS LIGANDOS OF 5- HYDROXITRIPTAMINE-6 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US6800640B2 (en) |
| EP (1) | EP1456206B1 (en) |
| JP (1) | JP4339123B2 (en) |
| KR (1) | KR20040077861A (en) |
| CN (1) | CN1620455A (en) |
| AR (1) | AR037907A1 (en) |
| AT (1) | ATE396191T1 (en) |
| AU (1) | AU2002360618B2 (en) |
| BR (1) | BR0215151A (en) |
| CA (1) | CA2470832C (en) |
| CO (1) | CO5590960A2 (en) |
| DE (1) | DE60226775D1 (en) |
| DK (1) | DK1456206T3 (en) |
| ES (1) | ES2305338T3 (en) |
| IL (1) | IL162242A0 (en) |
| MX (1) | MXPA04005886A (en) |
| NO (1) | NO20043099L (en) |
| PL (1) | PL370890A1 (en) |
| RU (1) | RU2004122094A (en) |
| TW (1) | TW200301251A (en) |
| WO (1) | WO2003053970A1 (en) |
| ZA (1) | ZA200405733B (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2222828B1 (en) | 2003-07-30 | 2006-04-16 | Laboratorios Del Dr. Esteve, S.A. | DERIVATIVES OF 1-SULPHONYLINDOLS, ITS PREPARATION AND ITS APPLICATION AS MEDICINES. |
| AU2004297235A1 (en) | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
| PE20060430A1 (en) | 2004-06-09 | 2006-05-25 | Glaxo Group Ltd | PYRROLOPYRIDINE DERIVATIVES AS MODULATORS OF CANNABINOID RECEPTORS |
| BRPI0514925A (en) | 2004-09-03 | 2008-07-01 | Yuhan Corp | pyrrol [2,3-c] pyridine derivatives and processes for preparing these |
| EP1805177B9 (en) * | 2004-09-03 | 2010-09-15 | Yuhan Corporation | Pyrrolo[3,2-c]pyridine derivatives and process for the preparation thereof |
| KR101142363B1 (en) | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | A composition for treating a cancer comprising pyrrolopyridine derivatives |
| EP1947085A1 (en) * | 2007-01-19 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Substituted indole sulfonamide compounds, their preparation and use as medicaments |
| KR101156845B1 (en) * | 2007-05-21 | 2012-06-18 | 에스지엑스 파마슈티컬스, 인코포레이티드 | Heterocyclic kinase modulators |
| BRPI0811225A2 (en) * | 2007-05-24 | 2014-10-29 | Memory Pharm Corp | 4'-REPLACED COMPOUND HAVING AFFINITY FOR THE 5-HT6 RECEIVER. |
| US20100016297A1 (en) * | 2008-06-24 | 2010-01-21 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| US20100022581A1 (en) * | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| US20100029629A1 (en) * | 2008-07-25 | 2010-02-04 | Memory Pharmaceuticals Corporation | Acyclic compounds having 5-ht6 receptor affinity |
| UA103195C2 (en) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| US20100056531A1 (en) * | 2008-08-22 | 2010-03-04 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| JP2012509342A (en) * | 2008-11-20 | 2012-04-19 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | Substituted pyrrolo [2,3-B] -pyridine and -pyrazine |
| US8119683B2 (en) * | 2009-08-10 | 2012-02-21 | Taipei Medical University | Aryl substituted sulfonamide compounds and their use as anticancer agents |
| US20130072495A1 (en) | 2010-05-14 | 2013-03-21 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
| AR081039A1 (en) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | QUINASA FUSIONED BICYCLE INHIBITORS |
| EP2714688B1 (en) | 2011-05-26 | 2016-02-24 | Daiichi Sankyo Company, Limited | Heterocyclic compounds as protein kinase inhibitors |
| RU2631482C2 (en) | 2011-07-22 | 2017-09-22 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Composition |
| WO2014031815A1 (en) | 2012-08-24 | 2014-02-27 | Glaxosmithkline Llc | Pyrazolopyrimidine compounds |
| WO2014081645A1 (en) | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
| KR20150085081A (en) | 2012-11-20 | 2015-07-22 | 글락소스미스클라인 엘엘씨 | Novel compounds |
| EP2922550B1 (en) | 2012-11-20 | 2017-04-19 | Glaxosmithkline LLC | Novel compounds |
| CN102977094A (en) * | 2012-11-30 | 2013-03-20 | 盛世泰科生物医药技术(苏州)有限公司 | Synthetic method of 2-hydroxy-1,5-naphthyridine |
| US9663498B2 (en) | 2013-12-20 | 2017-05-30 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
| WO2016004882A1 (en) | 2014-07-08 | 2016-01-14 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
| AU2017406159B2 (en) | 2017-03-30 | 2020-05-21 | XWPharma Ltd. | Bicyclic heteroaryl derivatives and preparation and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977131A (en) | 1997-04-09 | 1999-11-02 | Pfizer Inc. | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents |
| US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
| JP4597386B2 (en) * | 1999-04-21 | 2010-12-15 | エヌピーエス ファーマシューティカルス，インコーポレーテッド | Piperidine-indole compounds having 5-HT6 affinity |
| JP4969004B2 (en) * | 1999-08-12 | 2012-07-04 | エヌピーエス ファーマシューティカルズ，インク． | Azaindole with serotonin receptor affinity |
| US6476034B2 (en) | 2000-02-22 | 2002-11-05 | Bristol-Myers Squibb Company | Antiviral azaindole derivatives |
| RU2309157C2 (en) * | 2001-12-20 | 2007-10-27 | Уайт | Indolylalkylamine derivatives as 5-hydrohytriptamine-6 ligands |
| WO2006065710A1 (en) * | 2004-12-14 | 2006-06-22 | Wyeth | Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders |
-
2002
- 2002-12-04 TW TW091135173A patent/TW200301251A/en unknown
- 2002-12-17 PL PL02370890A patent/PL370890A1/en unknown
- 2002-12-17 KR KR10-2004-7009710A patent/KR20040077861A/en not_active Application Discontinuation
- 2002-12-17 ES ES02795890T patent/ES2305338T3/en not_active Expired - Lifetime
- 2002-12-17 DK DK02795890T patent/DK1456206T3/en active
- 2002-12-17 RU RU2004122094/04A patent/RU2004122094A/en not_active Application Discontinuation
- 2002-12-17 BR BR0215151-0A patent/BR0215151A/en not_active IP Right Cessation
- 2002-12-17 DE DE60226775T patent/DE60226775D1/en not_active Expired - Lifetime
- 2002-12-17 AT AT02795890T patent/ATE396191T1/en not_active IP Right Cessation
- 2002-12-17 IL IL16224202A patent/IL162242A0/en unknown
- 2002-12-17 EP EP02795890A patent/EP1456206B1/en not_active Expired - Lifetime
- 2002-12-17 CN CNA02828173XA patent/CN1620455A/en active Pending
- 2002-12-17 JP JP2003554686A patent/JP4339123B2/en not_active Expired - Fee Related
- 2002-12-17 CA CA2470832A patent/CA2470832C/en not_active Expired - Fee Related
- 2002-12-17 MX MXPA04005886A patent/MXPA04005886A/en active IP Right Grant
- 2002-12-17 WO PCT/US2002/040220 patent/WO2003053970A1/en active Application Filing
- 2002-12-17 AU AU2002360618A patent/AU2002360618B2/en not_active Ceased
- 2002-12-18 AR ARP020104952A patent/AR037907A1/en not_active Application Discontinuation
- 2002-12-19 US US10/323,263 patent/US6800640B2/en not_active Expired - Fee Related
-
2004
- 2004-06-15 CO CO04055770A patent/CO5590960A2/en not_active Application Discontinuation
- 2004-07-19 NO NO20043099A patent/NO20043099L/en not_active Application Discontinuation
- 2004-07-19 ZA ZA200405733A patent/ZA200405733B/en unknown
- 2004-08-19 US US10/922,678 patent/US7297705B2/en not_active Expired - Fee Related
-
2007
- 2007-11-16 US US11/941,479 patent/US7585876B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1620455A (en) | 2005-05-25 |
| DK1456206T3 (en) | 2008-09-08 |
| ZA200405733B (en) | 2005-10-19 |
| WO2003053970A1 (en) | 2003-07-03 |
| KR20040077861A (en) | 2004-09-07 |
| US20030171395A1 (en) | 2003-09-11 |
| TW200301251A (en) | 2003-07-01 |
| CA2470832C (en) | 2010-09-21 |
| BR0215151A (en) | 2004-10-19 |
| MXPA04005886A (en) | 2004-09-13 |
| RU2004122094A (en) | 2005-03-27 |
| US20080114023A1 (en) | 2008-05-15 |
| EP1456206B1 (en) | 2008-05-21 |
| US7297705B2 (en) | 2007-11-20 |
| AU2002360618A1 (en) | 2003-07-09 |
| CA2470832A1 (en) | 2003-07-03 |
| AU2002360618B2 (en) | 2009-01-08 |
| NO20043099L (en) | 2004-08-17 |
| ATE396191T1 (en) | 2008-06-15 |
| IL162242A0 (en) | 2005-11-20 |
| JP2005519046A (en) | 2005-06-30 |
| PL370890A1 (en) | 2005-05-30 |
| DE60226775D1 (en) | 2008-07-03 |
| AR037907A1 (en) | 2004-12-22 |
| JP4339123B2 (en) | 2009-10-07 |
| EP1456206A1 (en) | 2004-09-15 |
| US20050020598A1 (en) | 2005-01-27 |
| US6800640B2 (en) | 2004-10-05 |
| US7585876B2 (en) | 2009-09-08 |
| ES2305338T3 (en) | 2008-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5590960A2 (en) | DERIVATIVES OF AZAINDOLILALQUILAMINA AS LIGANDOS OF 5- HYDROXITRIPTAMINE-6 | |
| CO5590924A2 (en) | INDOLILALKYLAMINE DERIVATIVES AS 5-HYDROXITRIPTAMINE-6 LIGANDS | |
| CO5650164A2 (en) | HETROCICLIL-3-SULPHONYLINDAZOLS AS LIGANDS OF 5-HYDROXYTHYRIPTAMINE-6 | |
| CO5670358A2 (en) | DERIVATIVES OF 2-PIRIDONE AS INHIBITORS OF ELASTASA NEUTROFILA AND ITS USE | |
| PE20020456A1 (en) | QUINUCLIDINE GROUPS SUBSTITUTED WITH HETEROARYL FOR THE TREATMENT OF DISEASES | |
| AR038703A1 (en) | DERIVATIVES OF 5-PHENYLTIAZOL AND USE AS AN INHIBITOR OF QUINASA P I 3 | |
| RS50380B (en) | Tyrosine kinase inhibitors | |
| NO20060142L (en) | Cyclic tertiary amine compound | |
| AR054809A1 (en) | COMPOUNDS OF AMINO -5-HETEROARILO (5 MEMBERS) IMIDAZOLONE AND ITS USE FOR THE MODULATION OF B-SECRETASE | |
| CO5680430A2 (en) | DERIVATIVES OF 1-BENZOL-PIPERAZINE AS INHIBITORS OF THE GLYCINE CAPTURE FOR THE PSYCHOSIS TREATMENT | |
| PE20061297A1 (en) | CHROME AND CHROME DERIVED COMPOUNDS MODULATING THE SEROTONIN 5-HT2C RECEPTOR | |
| ATE417038T1 (en) | PHENYLPYRIDINE CARBONYL PIPERAZINE DERIVATIVES | |
| AR006720A1 (en) | A COMPOUND DERIVED FROM HETERO-CYCLIC AZAHEXANE, ITS USE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION, PROCEDURE FOR PREPARING IT AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT | |
| TR200401413T1 (en) | Dibenzylamine compounds and their pharmaceutical uses | |
| CO5680412A2 (en) | ETHYLAMIN BETA 2 ADRENERGIC RECEIVER AGONISTS REPLACED WITH AMINO | |
| AR045805A1 (en) | QUINOLONAS Y NAFTRIDONAS 7- AMINO ALQUIDENIL - HETEROCICLICAS | |
| DE60334243D1 (en) | PYRIDINE N-OXIDE COMPOUNDS ALSPHOSPHODIESTERASE-4-INHIBITORS | |
| ES2179005T3 (en) | CHROMENE COMPOUND | |
| DE602005022108D1 (en) | N-SUBSTITUTED IMIDS AS POLYMERISATIOSINITIATORS | |
| CO4940446A1 (en) | COMPOUNDS 4-AMINOPIRIDE [2,3-D] PIRIMIDINE 5,7-DISSTITUTED | |
| CO5700777A2 (en) | DERIVATIVES OF 4- (2-PHENYL SULFANYL-PHENYL) -1,2,3,6-TETRAHYDROPIRIDINE AS INHIBITORS OF SEROTONIN RECAPTATION | |
| AR015514A1 (en) | AMIDA COMPOUND, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | |
| CO5660258A2 (en) | IMIDAZOL III DERIVATIVES | |
| ECSP088189A (en) | DERIVATIVES OF 3-SULFONYLINDAZOL REPLACED COMOLIGANDOS OF 5-HIDROXITRIPTAMINA-6 | |
| ATE420131T1 (en) | SILICON AND POLYSILYLCYAMELURATES AND CYANURATES, PROCESS FOR THEIR PRODUCTION AND THEIR USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |